Should I buy or sell BeiGene stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BGNE shares. View BGNE analyst ratings or view top-rated stocks .

What is BeiGene's stock price target for 2024?

9 brokerages have issued twelve-month target prices for BeiGene's shares. Their BGNE share price targets range from $161.00 to $345.00. On average, they anticipate the company's stock price to reach $251.70 in the next year. This suggests a possible upside of 90.9% from the stock's current price. View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts .

How have BGNE shares performed in 2024?

BeiGene's stock was trading at $180.36 on January 1st, 2024. Since then, BGNE stock has decreased by 26.9% and is now trading at $131.86. View the best growth stocks for 2024 here .

When is BeiGene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BGNE earnings forecast .

How were BeiGene's earnings last quarter?

BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings data on Monday, February, 26th. The company reported ($3.53) earnings per share for the quarter, beating analysts' consensus estimates of ($3.61) by $0.08. The business had revenue of $634.40 million for the quarter, compared to the consensus estimate of $632.52 million. BeiGene had a negative trailing twelve-month return on equity of 23.12% and a negative net margin of 35.86%. The firm's quarterly revenue was up 66.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($4.29) EPS.

What ETFs hold BeiGene's stock?

ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Morningstar US Small Growth (MSGR) , VanEck Biotech ETF (BBH) , Loncar China Biopharma ETF (CHNA) , Virtus LifeSci Biotech Products ETF (BBP) , iShares Biotechnology ETF (IBB) , Global X Aging Population ETF (AGNG) and Invesco Nasdaq Biotechnology ETF (IBBQ) . ProShares Ultra Nasdaq Biotechnology (BIB) .

What is John V. Oyler's approval rating as BeiGene's CEO?

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com . John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

What other stocks do shareholders of BeiGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , CRISPR Therapeutics (CRSP) , Block (SQ) , Intuitive Surgical (ISRG) , JD.com (JD) , Intel (INTC) , Baidu (BIDU) , Marvell Technology (MRVL) and Cisco Systems (CSCO) .

When did BeiGene IPO?

BeiGene (BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.

How do I buy shares of BeiGene?

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BGNE

BeiGene (BGNE) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Free BGNE Stock Alerts

$132.66

+0.80 (+0.61%)

(As of 09:52 AM ET)

Compare

Today's Range: $131.40
▼
$132.98
50-Day Range: $134.05
▼
$179.69
52-Week Range: $131.28
▼
$266.67

Volume: 9,157 shs
Average Volume: 257,997 shs
Market Capitalization: $12.69 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $251.70

Get BeiGene alerts:

BeiGene MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 90.9% Upside
$251.70 Price Target
Short Interest: Bearish
1.81% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.56
Based on 8 Articles This Week
Insider Trading: Selling Shares
$10.22 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($8.87) to ($2.34) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

Medical Sector

593rd out of 913 stocks

Pharmaceutical Preparations Industry

275th out of 422 stocks

3.4

Analyst's Opinion

Consensus Rating
BeiGene has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
BeiGene has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
1.81% of the outstanding shares of BeiGene have been sold short.
Short Interest Ratio / Days to Cover
BeiGene has a short interest ratio ("days to cover") of 6.6.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
BeiGene does not currently pay a dividend.
Dividend Growth
BeiGene does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BGNE.

2.5

News and Social Media Coverage

News Sentiment
BeiGene has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for BeiGene this week, compared to 4 articles on an average week.
Search Interest
Only 4 people have searched for BGNE on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added BeiGene to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BeiGene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,222,381.00 in company stock.
Percentage Held by Insiders
Only 7.40% of the stock of BeiGene is held by insiders.
Percentage Held by Institutions
48.55% of the stock of BeiGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BeiGene are expected to grow in the coming year, from ($8.87) to ($2.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BeiGene is -15.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BeiGene is -15.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BeiGene has a P/B Ratio of 3.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About BeiGene Stock (NASDAQ:BGNE)

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

BGNE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BGNE Stock News Headlines

April 12, 2024 | insidertrades.com

Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) CEO Sells 26,716 Shares of Stock

April 14, 2024 | nasdaq.com

BeiGene Becomes Oversold (BGNE)

April 18, 2024 | DTI (Ad)

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

April 13, 2024 | investing.com

BeiGene CEO John Oyler sells shares worth over $7.4 million

April 13, 2024 | americanbankingnews.com

John Oyler Sells 26,716 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

April 9, 2024 | americanbankingnews.com

Bank of America Lowers BeiGene (NASDAQ:BGNE) Price Target to $164.30

March 27, 2024 | markets.businessinsider.com

4 Analysts Assess BeiGene: What You Need To Know

March 27, 2024 | finance.yahoo.com

Shareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past week

April 18, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

March 27, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)

March 22, 2024 | investing.com

BeiGene appoints new principal accounting officer

March 16, 2024 | finance.yahoo.com

BGNE Apr 2024 140.000 put

March 16, 2024 | finance.yahoo.com

BGNE Apr 2024 220.000 call

March 16, 2024 | finance.yahoo.com

BGNE Apr 2024 125.000 put

March 16, 2024 | ca.finance.yahoo.com

BGNE Apr 2024 180.000 call

March 16, 2024 | ca.finance.yahoo.com

BGNE Apr 2024 135.000 put

March 14, 2024 | msn.com

BeiGene gets FDA approval for esophageal cancer drug Tevimbra

March 14, 2024 | finance.yahoo.com

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

March 8, 2024 | msn.com

FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer

March 8, 2024 | seekingalpha.com

BeiGene Still Bleeding Red Ink Despite Blockbuster Drug

March 7, 2024 | msn.com

BeiGene gets FDA accelerated approval for Brukinsa for follicular lymphoma

March 7, 2024 | businesswire.com

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

March 7, 2024 | reuters.com

US FDA approves expanded use of BeiGene's blood cancer drug

March 6, 2024 | finance.yahoo.com

BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

February 29, 2024 | finanznachrichten.de

BeiGene, Ltd.: BeiGene Announces New Efficacy Analysis Comparing BRUKINSA vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

February 29, 2024 | finance.yahoo.com

BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

February 28, 2024 | finance.yahoo.com

BeiGene Full Year 2023 Earnings: Beats Expectations

See More Headlines

Receive BGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BGNE
CUSIP: N/A
CIK: 1651308
Web: www.beigene.com
Phone: (345) 949-4123
Fax: N/A
Employees: 10,600
Year Founded: 2010

Price Target and Rating

Average Stock Price Target: $251.70
High Stock Price Target: $345.00
Low Stock Price Target: $161.00
Potential Upside/Downside: +90.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-881,710,000.00
Net Margins: -35.86%
Pretax Margin: -33.59%
Return on Equity: -23.12%
Return on Assets: -15.32%

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 2.32
Quick Ratio: 2.09

Sales & Book Value

Annual Sales: $2.46 billion
Price / Sales: 5.13
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $37.10 per share
Price / Book: 3.55

Miscellaneous

Outstanding Shares: 95,640,000
Free Float: 88,563,000
Market Cap: $12.61 billion
Optionable: Optionable
Beta: 0.61

Social Links

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. John V. Oyler (Age 56)
Co-Founder, Executive Chairman & CEO
Comp: $2.05M
Dr. Xiaobin Wu Ph.D. (Age 62)
President & COO
Comp: $1.69M
Dr. Xiaodong Wang Ph.D. (Age 61)
Co- Chairman of Scientific Advisory Board & Non-Executive Director Co-Founder
Comp: $250k
Mr. Wang Lai Ph.D. (Age 47)
Global Head of R&D
Comp: $996.92k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in BeiGene, Ltd.:

BeiGene, Ltd. has a diverse portfolio of oncology medicines, including advanced treatments like BRUKINSA and TEVIMBRA, which cater to a wide range of cancers.
The company is actively developing a pipeline of innovative inhibitors and antibodies, such as Sonrotoclax and Zanidatamab, which shows promising potential for future growth.
Collaborations with reputable companies like Amgen Inc. and Novartis AG indicate strong partnerships that could lead to further advancements and market opportunities.
BeiGene, Ltd. has a global presence, engaging in the development and commercialization of oncology medicines worldwide, providing exposure to diverse markets.
Considering the recent positive market sentiment towards the pharmaceutical industry, BeiGene, Ltd. could benefit from favorable industry trends.

Cons

Investors should be bearish about investing in BeiGene, Ltd. for these reasons:

Market volatility and regulatory challenges in the pharmaceutical industry could impact the company's growth trajectory and stock performance.
Competition in the oncology medicines market is intense, with established players and new entrants posing a threat to BeiGene, Ltd.'s market share.
Investing in pharmaceutical companies like BeiGene, Ltd. carries inherent risks related to clinical trial outcomes, regulatory approvals, and market acceptance of new products.
The current stock price of BeiGene, Ltd. may be influenced by various factors, including market conditions, industry news, and company-specific developments, which could lead to fluctuations in share value.
Global economic uncertainties and geopolitical factors may impact the demand for oncology medicines and affect BeiGene, Ltd.'s financial performance.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these BeiGene pros and cons to contact@marketbeat.com.

BGNE Stock Analysis - Frequently Asked Questions

Should I buy or sell BeiGene stock right now?: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.
What is BeiGene's stock price target for 2024?: 9 brokerages have issued twelve-month target prices for BeiGene's shares. Their BGNE share price targets range from $161.00 to $345.00. On average, they anticipate the company's stock price to reach $251.70 in the next year. This suggests a possible upside of 90.9% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.
How have BGNE shares performed in 2024?: BeiGene's stock was trading at $180.36 on January 1st, 2024. Since then, BGNE stock has decreased by 26.9% and is now trading at $131.86.
View the best growth stocks for 2024 here.
When is BeiGene's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BGNE earnings forecast.
How were BeiGene's earnings last quarter?: BeiGene, Ltd. (NASDAQ:BGNE) posted its quarterly earnings data on Monday, February, 26th. The company reported ($3.53) earnings per share for the quarter, beating analysts' consensus estimates of ($3.61) by $0.08. The business had revenue of $634.40 million for the quarter, compared to the consensus estimate of $632.52 million. BeiGene had a negative trailing twelve-month return on equity of 23.12% and a negative net margin of 35.86%. The firm's quarterly revenue was up 66.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($4.29) EPS.
What ETFs hold BeiGene's stock?: ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Morningstar US Small Growth (MSGR), VanEck Biotech ETF (BBH), Loncar China Biopharma ETF (CHNA), Virtus LifeSci Biotech Products ETF (BBP), iShares Biotechnology ETF (IBB), Global X Aging Population ETF (AGNG) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB).

What is John V. Oyler's approval rating as BeiGene's CEO?: 58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.
What other stocks do shareholders of BeiGene own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).
When did BeiGene IPO?: BeiGene (BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company served as the underwriters for the IPO and Baird was co-manager.
How do I buy shares of BeiGene?: Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BGNE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BeiGene (BGNE) Stock Price, News & Analysis

BeiGene MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About BeiGene Stock (NASDAQ:BGNE)

BGNE Stock Price History

BGNE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy BeiGene Stock? BGNE Pros and Cons Explained

Pros

Cons

BGNE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™